New blood test could revolutionize colon cancer staging before surgery

NCT ID NCT07255729

Recruiting now Diagnosis Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study is testing whether a blood test that looks at tiny genetic particles called microRNAs can help doctors better stage colon cancer before surgery. The test uses machine learning to analyze these particles and predict if the cancer is aggressive enough to need chemotherapy before an operation. Researchers will collect blood samples from 400 colon cancer patients to see if the test can accurately identify high-risk cases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EXPOSE assay (blood test for exosomal microRNAs)
What this could lead to: If successful, this blood test could help doctors more accurately determine colon cancer stage and who needs chemotherapy before surgery, potentially improving treatment decisions.
What could go wrong: This is an early-stage diagnostic study, not a treatment trial. The test may not prove accurate enough in practice, and results may not change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.